Cash figures as of 2026-07-15. Database snapshot: 2026-09-21.
Price history
Loading AEON daily closes…
Loading price history…
Pipeline assets
ABP-450
Stage not disclosed · ActiveModality: botulinum toxin complex injection (biosimilar)
Aliases prabotulinumtoxinA
Partnerships Daewoong (exclusive license and supply for therapeutic indications in covered territories)
Indications
therapeutic indications (BOTOX biosimilar)(Stage not disclosed)
Status note Developing ABP-450 as a biosimilar to BOTOX via 351(k) BLA; analytical studies commenced Q4 2024; prior 351(a) therapeutic development not currently pursued; no discontinuation disclosed.
Per-asset detail extracted from the 10-Q filed 2026-08-12. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.
No lead program on file for this company.
No active ClinicalTrials.gov trials matched to this company as sponsor or collaborator.
No specialist-fund holders in 13F data for this company.
Get the weekly biotech catalyst rundown. Cash runways, financings, and trial readouts for all 714 stocks.